Background-Cardiac troponin I and T (cTnI and cTnT) are specific biochemical serum markers for acute myocardial infarction (AMI). However, cTnI diagnostic assays are plagued by difficulties, resulting in Ն20-fold differences in measured values. These discrepancies may result from the release of the numerous cTnI modification products that are present in ischemic myocardium. The resolution of these discrepancies requires an investigation of the exact forms of cTnI present in the bloodstream of patients after myocardial injury. Methods and Results-A western blot-direct serum analysis protocol was developed that allowed us to detect intact cTnI and a spectrum of up to 11 modified products in the serum from patients with AMI. For the first time, we document both a cTnI degradation pattern and the existence of phosphorylated cTnI in serum. The number and extent of these modifications reflect patterns similar to the time profiles of the routine clinical serum markers of total creatine kinase, creatine kinase-MB, and cTnI (determined by ELISA). Data from in vitro experiments, which were undertaken to study the degradation of human recombinant cTnI and cTnT when spiked in serum, indicate that some modification products present in patient serum existed in the myocardium and that recombinant cTnI alteration dramatically reduces the detectability of cTnI by the Immuno1 assay over time (our assay was unaffected). Key Words: troponin Ⅲ myocardial infarction Ⅲ biological markers Ⅲ diagnosis Ⅲ blotting, western I t is widely accepted that the presence of cardiac troponin I or T (cTnI or cTnT) in blood serum indicates myocardial damage; thus, cTnI and cTnT are considered specific biochemical markers for acute myocardial infarction (AMI). [1][2][3] Despite the widespread use of cTnI and cTnT detection as a diagnostic tool in acute coronary syndromes, problems arise from variations in the sensitivity, selectivity, and specificity of various commercially available diagnostic cTnI immunoassay kits. 4 -7 These differences are due to (1) the lack of mass standardization, 8 -10 (2) the presence of post-translationally modified cTnI in the serum, and (3) variations in antibody cross-reactivities to the various detectable forms of cTnI. 10,11 Although cTnT is thought to be unaffected by such problems, this remains to be proven: thus far, only one manufacturer has marketed a diagnostic cTnT assay. The underlying reason for this controversy is the inability to determine reliably the exact forms and amounts of cTnI and cTnT present in blood. Conclusions-ThisOn the basis of previous findings, some have proposed that only a small amount of free intact cTnI is detectable in blood, with the predominant form being a complex between cTnI and cardiac tropinin C. 11-13 However, post-translational modifications, including selective degradation, covalent complex formation, and phosphorylation of cTnI, occur in the myocardium of ischemic-reperfused rat hearts 14 -16 and human postischemic myocardium. 17,18 In fact, these modification products, and ...

Several pyroglutamylaminoacyl-tRNA's were prepared by T4 RNA ligase mediated condensation of synthetic pyroglutamylaminoacyl-pCpA's with tRNA's from which the last two nucleotides at the 3'-end had been removed. The derived pyroglutamylaminoacyl-tRNA's were incubated in the presence of calf liver pyroglutamate aminopeptidase, which effected their conversion to free aminoacyl-tRNA's. The lack of contaminating esterase activities in the pyroglutamate aminopeptidase was verified by direct assay for the presence of the aminoacyl moieties in the formed aminoacyl-tRNA's and by the use of the deblocked aminoacyl-tRNA's as acceptors in the peptidyltransferase reaction using an Escherichia coli ribosomal system. These findings provide the wherewithal for a detailed investigation of the substrate specificity of the peptidyltransferase center and for the elaboration of polypeptides containing modified amino acids at predetermined sites.

Background: The extracellular domain of the HER-2/neu oncogene product is increased in sera of some patients with epithelial cancers. Our aim was to develop an automated serum assay for the extracellular domain of the HER-2/neu protein. Methods: We used a monoclonal antibody labeled with fluorescein for capture and a monoclonal Fab′ fragment labeled with alkaline phosphatase for detection. Separation of bound and free detection conjugate was performed with magnetizable particles coated with monoclonal antibody to fluorescein. Alkaline phosphatase activity was measured kinetically at 405 or 450 nm. Results: The assay was linear from 0.1 to 250 μg/L. No hook effect was evident up to 10 000 μg/L. Within-run imprecision (CV) was 0.8–1.2%, and total imprecision was 1.1–1.7%. Cross-reactivity with human epidermal growth factor receptor, which has extensive homology with HER-2/neu extracellular domain, was <0.6%. Human anti-mouse antibodies, heterophilic antibodies, and rheumatoid factor did not interfere, nor did the therapeutic monoclonal antibody Herceptin®. In 51 healthy females, the mean value was 9.3 μg/L with a range of 6.4–14.0 μg/L. No reagent lot-to-lot variability was detected over four lots of reagents tested. Conclusion: The Bayer Immuno 1TM assay for HER-2/neu was precise and resistant to interferences, characteristics that are essential for longitudinal monitoring of cancer patients.

Uridine 5'-phosphate (UMP) synthase is a multifunctional protein that contains the last two enzyme activities for the de novo biosynthesis of UMP, orotate phosphoribosyltransferase (EC 2.4.2.10) and orotidine-5'-phosphate (OMP) decarboxylase (EC 4.1.1.23). The native enzyme from mouse Ehrlich ascites cells exists in at least three distinct aggregation/conformation states as measured by sedimentation in sucrose gradients: a 3.6S monomer, a 5.1S dimer, and a conformationally altered 5.6S dimer. It has previously been reported that a variety of ligands (of which the most effective is OMP) mediate the conversion of the 3.6S monomer to the two types of dimers. Initial velocity studies with the enzyme in the different native states show that all three forms of UMP synthase have phosphoribosyltransferase activity but that the OMP decarboxylase is either uniquely or at least predominantly associated with the 5.6S form. Activation of this enzyme activity by the substrate appears to be the result of both a dimerization and a conformation step.

A cell-free protein biosynthesizing system prepared from Escherichia coli CF300 was found to synthesize E. coli tryptophan synthase alpha subunit in a time-dependent manner when programmed with pBN69 plasmid DNA. This plasmid contains the trp promoter from Serratia marcescens adjacent to the coding region of E. coli tryptophan synthase alpha protein [Nichols, B.P., & Yanofsky, C. (1983) Methods Enzymol. 101, 155-164]. The synthesized tryptophan synthase alpha subunit was found to be indistinguishable from authentic alpha subunit protein when analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and to have the same specific activity for catalyzing the conversion of indole----L-tryptophan by tryptophan synthase beta 2 subunit, as well as the conversion of indole + glyceraldehyde 3-phosphate to indole-3-glycerol phosphate. In the absence of exogenously added phenylalanine, admixture of E. coli phenylalanyl-tRNAPhe to the protein biosynthesizing system stimulated the production of functional alpha protein; the analogous result was obtained when valine was replaced by E. coli valyl-tRNAVal. The ability of a misacylated tRNA to participate in alpha protein synthesis in this system was established by the use of E. coli phenylalanyl-tRNAVal in the absence of added valine. Protein biosynthesis proceeded normally and gave a product having the approximate molecular weight of tryptophan synthase alpha subunit; as expected, this polypeptide lacked catalytic activity.